AVROBIO Stock Forecast, Price & News

AVROBIO (NASDAQ:AVRO) Frequently Asked Questions

Is AVROBIO a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVROBIO stock.
View analyst ratings for AVROBIO or view top-rated stocks.

How has AVROBIO's stock been impacted by Coronavirus?

AVROBIO's stock was trading at $18.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AVRO shares have decreased by 80.1% and is now trading at $3.59.
View which stocks have been most impacted by COVID-19.

When is AVROBIO's next earnings date?

AVROBIO is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for AVROBIO.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.75).
View AVROBIO's earnings history.

What price target have analysts set for AVRO?

8 Wall Street analysts have issued 1-year target prices for AVROBIO's shares. Their forecasts range from $7.00 to $36.00. On average, they expect AVROBIO's share price to reach $21.13 in the next twelve months. This suggests a possible upside of 488.4% from the stock's current price.
View analysts' price targets for AVROBIO or view top-rated stocks among Wall Street analysts.

Who are AVROBIO's key executives?

AVROBIO's management team includes the following people:

• Geoff MacKay, President, Chief Executive Officer & Director
• Erik Ostrowski, Chief Financial Officer & Treasurer
• Christopher Mason, Chief Scientific Officer
• Kim Raineri, Chief Manufacturing & Technology Officer
• Essra Ridha, Chief Medical Officer

Who are some of AVROBIO's key competitors?

Some companies that are related to AVROBIO include Aligos Therapeutics (ALGS), Adaptimmune Therapeutics (ADAP), Aura Biosciences (AURA), Precision BioSciences (DTIL), Talaris Therapeutics (TALS), Graphite Bio (GRPH), Tarsus Pharmaceuticals (TARS), Aerie Pharmaceuticals (AERI), Athira Pharma (ATHA), Taysha Gene Therapies (TSHA), Ikena Oncology (IKNA), Autolus Therapeutics (AUTL), Poseida Therapeutics (PSTX), Molecular Partners (MOLN) and Curis (CRIS).
View all of AVRO's competitors.

What other stocks do shareholders of AVROBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS).

When did AVROBIO IPO?

(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.28%), BioImpact Capital LLC (1.97%), Millennium Management LLC (1.92%), Geode Capital Management LLC (1.32%), Renaissance Technologies LLC (0.93%) and Morgan Stanley (0.82%). Company insiders that own AVROBIO stock include Christopher Paige, Geoffrey Mackay and Philip J Vickers.
View institutional ownership trends for AVROBIO.

Which major investors are selling AVROBIO stock?

AVRO stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Point72 Asset Management L.P., Citigroup Inc., Morgan Stanley, Geode Capital Management LLC, New York State Common Retirement Fund, Dimensional Fund Advisors LP, and First Republic Investment Management Inc..
View insider buying and selling activity for AVROBIO or view top insider-selling stocks.

Which major investors are buying AVROBIO stock?

AVRO stock was purchased by a variety of institutional investors in the last quarter, including BioImpact Capital LLC, Eversept Partners LP, Renaissance Technologies LLC, Millennium Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, GSA Capital Partners LLP, and BlackRock Inc..
View insider buying and selling activity for AVROBIO or or view top insider-buying stocks.

How do I buy shares of AVROBIO?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $3.59.

How much money does AVROBIO make?

AVROBIO has a market capitalization of $156.70 million. The company earns $-119.71 million in net income (profit) each year or ($2.87) on an earnings per share basis.

How many employees does AVROBIO have?

AVROBIO employs 121 workers across the globe.

What is AVROBIO's official website?

The official website for AVROBIO is www.avrobio.com.

Where are AVROBIO's headquarters?

AVROBIO is headquartered at ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139.

How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 914-8420 or via email at [email protected].